Filing Details

Accession Number:
0001209191-11-038002
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-07-05 22:12:21
Reporting Period:
2011-07-01
Filing Date:
2011-07-05
Accepted Time:
2011-07-05 21:12:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103390 Ardea Biosciences Inc. RDEA Pharmaceutical Preparations (2834) 943200380
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1370348 A Craig Johnson 4939 Directors Place
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-07-01 2,000 $12.16 2,000 No 4 M Direct
Common Stock Disposition 2011-07-01 1,523 $26.13 477 No 4 S Direct
Common Stock Disposition 2011-07-01 477 $26.60 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2011-07-01 2,000 $0.00 2,000 $12.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,500 2019-01-01 No 4 M Direct
Footnotes
  1. The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 24, 2011.
  2. The range of sales prices received was $25.41 to $26.40. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
  3. The range of sales prices received was $26.51 to $26.68. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
  4. Immediately exercisable, subject to a right of repurchase on behalf of the Issuer that lapsed one year from the grant date.